Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov:10:100208.
doi: 10.1016/j.lanepe.2021.100208. Epub 2021 Sep 6.

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber  1   2 , Liina Tserel  3 , Kadri Kangro  4 , Epp Sepp  2 , Virge Jürjenson  1 , Ainika Adamson  1 , Liis Haljasmägi  3 , Anna Pauliina Rumm  3 , Regina Maruste  3 , Jaanika Kärner  3 , Joachim M Gerhold  4 , Anu Planken  4   5 , Mart Ustav  4 , Kai Kisand  3 , Pärt Peterson  3
Affiliations

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al. Lancet Reg Health Eur. 2021 Nov.

Abstract

Background: SARS-CoV-2 mRNA vaccines have proven high efficacy, however, limited data exists on the duration of immune responses and their relation to age and side effects.

Methods: We studied the antibody and memory T cell responses after the two-dose BNT162b2 vaccine in 122 volunteers up to 6 months and correlated the findings with age and side effects.

Findings: We found a robust antibody response to Spike protein after the second dose. However, the antibody levels declined at 12 weeks and 6 months post-vaccination, indicating a waning of the immune response over time. At 6 months after the second dose, the Spike antibody levels were similar to the levels in persons vaccinated with one dose or in COVID-19 convalescent individuals. The antibodies efficiently blocked ACE2 receptor binding to SARS-CoV-2 Spike protein of five variants of concern at one week but this was decreased at three months. 87% of individuals developed Spike-specific memory T cell responses, which were lower in individuals with increased proportions of immunosenescent CD8+ TEMRA cells. We found antibody response to correlate negatively with age and positively with the total score of vaccination side effects.

Interpretation: The mRNA vaccine induces a strong antibody response to SARS-CoV-2 and five VOCs at 1 week post-vaccination that decreases thereafter. T cell responses, although detectable in the majority, were lower in individuals with higher T cell immunosenescence. The deterioration of vaccine response suggests the need to monitor for the potential booster vaccination.

Keywords: SARS-CoV-2 mRNA vaccine; adverse effects; age; dynamics of the immune response.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose.

Figures

Fig 1
Fig. 1
Antibody responses in individuals vaccinated with Pfizer-BioNTech Comirnaty vaccine. S-RBD IgG levels before vaccination (B1D, n=88), after the single (B2D, n=111) and two-dose immunizations (1 week (1wA2D, n=106); 6 weeks (6wA2D, n=89), 12 weeks (12wA2D, n=90), and 6 months (6mA2D; n=84) in vaccinated individuals compared with post-infection levels in patients recovered from COVID-19 (COVID-19, n=97) and pre-COVID-19 negative controls (NC, n=50). The box plot comparisons were performed with the Kruskall-Wallis test and Dunn's multiple testing correction; p-values >0·0001 are reported as exact numbers.
Fig 2
Fig. 2
Inhibition of ACE2-trimeric Spike interaction by vaccine-induced antibodies. Serum antibody capacities to block the interaction of ACE2 receptor and Spike protein with the modifications of wild type (wt, Wuhan, n=49) and five VOCs of Alpha (B.1.1.7, n=49), Beta (B.1.351, n=49), Gamma (P.1, n=49), Delta (B.1.617.2, n=48), and Kappa (B.1.617.1, n=48) were analyzed before the vaccination (B1D), one (1wA2D) and 12 (12wA2D) weeks after the second dose. The dotted line indicates the relative OD value of 0·75, which is a threshold for sufficient blocking of ACE2 binding. The box plot comparisons were performed with the Kruskal-Wallis test with Dunn's multiple testing correction; p-values >0·0001 are reported as exact numbers.
Fig 3
Fig. 3
Spike-specific T cell responses in vaccinated individuals 12 weeks after the second dose. (A) Post-vaccination frequency of S-specific CD4+ (n=79) and CD8+ (n=78) T cells and (B) the percentage of Spike-specific CD4+ T cells in individuals with lower (<40%, n=61) and higher (>40%, n=17) proportions of CD8+ TEMRA cells in their peripheral blood. The data were analyzed with the Mann-Whitney test, two-tailed p-values are given as exact numbers.
Fig 4
Fig. 4
Post-vaccination antibody responses correlate negatively with age. Spearman correlation analysis between age and S-RBD IgG levels before the second dose (B2D, n=111), 1 week (1wA2D, n=106), 6 weeks (6wA2D, n=89), 12 weeks (12wA2D, n=90), and 6 months (6mA2D, n=84) after the second dose. Spearman correlation coefficient and exact p-values are given.
Fig 5
Fig. 5
Post-vaccination antibody responses correlate positively with the total score of side effects. Spearman correlation analysis between total score of side effects and S-RBD IgG levels before the second dose (B2D, n=84), 1 week (1wA2D, n=85), 6 weeks (6wA2D, n=82), 12 weeks (12wA2D, n=82), and 6 months (6mA2D; n=75) after the second dose. Spearman correlation coefficient and exact p-values are given.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shrotri M, Fragaszy E, Geismar C, et al. Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch) medRxiv. 2021 2021.05.12.21257102.
    1. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 - PMC - PubMed
    1. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021 - PMC - PubMed
    1. Jalkanen P, Kolehmainen P, Häkkinen HK, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021;12(1):3991. - PMC - PubMed
    1. Goel RR, Apostolidis SA, Painter MM, et al. Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination. medRxiv. 2021 - PMC - PubMed